HomeCompareOCPNY vs SBUX

OCPNY vs SBUX: Dividend Comparison 2026

OCPNY yields 6.78% · SBUX yields 2.75%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 OCPNY wins by $36894.62M in total portfolio value
10 years
OCPNY
OCPNY
● Live price
6.78%
Share price
$18.00
Annual div
$1.22
5Y div CAGR
100%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$36894.78M
Annual income
$35,878,815,378.93
Full OCPNY calculator →
SBUX
SBUX
● Live price
2.75%
Share price
$89.59
Annual div
$2.46
5Y div CAGR
48.3%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$157.5K
Annual income
$65,840.13
Full SBUX calculator →

Portfolio growth — OCPNY vs SBUX

📍 OCPNY pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodOCPNYSBUX
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, OCPNY + SBUX cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
OCPNY pays
SBUX pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

OCPNY
Annual income on $10K today (after 15% tax)
$576.66/yr
After 10yr DRIP, annual income (after tax)
$30,496,993,072.09/yr
SBUX
Annual income on $10K today (after 15% tax)
$233.40/yr
After 10yr DRIP, annual income (after tax)
$55,964.11/yr
At 15% tax rate, OCPNY beats the other by $30,496,937,107.98/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of OCPNY + SBUX for your $10,000?

OCPNY: 50%SBUX: 50%
100% SBUX50/50100% OCPNY
Portfolio after 10yr
$18447.47M
Annual income
$17,939,440,609.53/yr
Blended yield
97.25%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on SBUX right now

OCPNY
No analyst data
SBUX
Analyst Ratings
28
Buy
27
Hold
3
Sell
Consensus: Buy
Price Target
$104.00
+16.1% upside vs current
Range: $90.00 — $120.00
Altman Z
2.6
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

OCPNY buys
0
SBUX buys
0
No recent congressional trades found for OCPNY or SBUX in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricOCPNYSBUX
Forward yield6.78%2.75%
Annual dividend / share$1.22$2.46
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR100%48.3%
Portfolio after 10y$36894.78M$157.5K
Annual income after 10y$35,878,815,378.93$65,840.13
Total dividends collected$36824.86M$127.5K
Payment frequencyquarterlyquarterly
SectorStockConsumer Discretionary

Year-by-year: OCPNY vs SBUX ($10,000, DRIP)

YearOCPNY PortfolioOCPNY Income/yrSBUX PortfolioSBUX Income/yrGap
1← crossover$12,057$1,356.84$11,107$407.21+$950.00OCPNY
2$15,959$3,057.79$12,512$626.87+$3.4KOCPNY
3$24,641$7,565.10$14,366$978.69+$10.3KOCPNY
4$48,199$21,833.39$16,929$1,557.50+$31.3KOCPNY
5$131,400$79,827.21$20,658$2,543.80+$110.7KOCPNY
6$547,374$406,775.39$26,406$4,302.22+$521.0KOCPNY
7$3,752,986$3,167,296.52$35,877$7,622.00+$3.72MOCPNY
8$44,606,539$40,590,843.20$52,741$14,352.64+$44.55MOCPNY
9$949,499,111$901,770,114.43$85,676$29,243.03+$949.41MOCPNY
10$36,894,779,427$35,878,815,378.93$157,513$65,840.13+$36894.62MOCPNY

OCPNY vs SBUX: Complete Analysis 2026

OCPNYStock

Olympus Corporation manufactures and sells precision machineries and instruments worldwide. It operates through four segments: Endoscopic Solutions Business, Therapeutic Solutions Business, Scientific Solutions Business, and Others. The Endoscopic Solutions Business segment offers gastrointestinal and surgical endoscopes, endoscopy system, and repair services. The Therapeutic Solutions Business segment provides urology, gynecology, ear, nose, and throat products; endo-therapy and energy devices; and surgical single-use devices. The Scientific Solutions Business segment offers biological and industrial microscopes, industrial endoscopes and videoscopes, non-destructive testing equipment, and X-ray fluorescence (XRF) analyzers. The Others segment offers biomedical materials and orthopedic equipment. The company also offers medical devices, such as surgical microscopes, endoscope reprocessors, electrosurgical devices, and respiratory-endotherapy devices, as well as system integration and maintenance/services. The company was formerly known as Olympus Optical Co., Ltd. and changed its name to Olympus Corporation in October 2003. Olympus Corporation was founded in 1919 and is headquartered in Tokyo, Japan.

Full OCPNY Calculator →

SBUXConsumer Discretionary

Starbucks Corporation, together with its subsidiaries, operates as a roaster, marketer, and retailer of specialty coffee worldwide. The company operates through three segments: North America, International, and Channel Development. Its stores offer coffee and tea beverages, roasted whole beans and ground coffees, single serve products, and ready-to-drink beverages; and various food products, such as pastries, breakfast sandwiches, and lunch items. The company also licenses its trademarks through licensed stores, and grocery and foodservice accounts. The company offers its products under the Starbucks, Teavana, Seattle's Best Coffee, Evolution Fresh, Ethos, Starbucks Reserve, and Princi brands. As of October 3, 2021, it operated 16,826 company-operated and licensed stores in North America; and 17,007 company-operated and licensed stores internationally. The company was founded in 1971 and is based in Seattle, Washington.

Full SBUX Calculator →
📬

Get this OCPNY vs SBUX comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

OCPNY vs SCHDOCPNY vs JEPIOCPNY vs OOCPNY vs KOOCPNY vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.